DEA Bans Mind-Bending 3-MeO-PCP in Schedule I Crackdown
Published Date: 3/23/2026
Rule
Summary
Starting April 22, 2026, the DEA is putting 3-methoxyphencyclidine (3-MeO-PCP) into Schedule I, meaning it’s now officially a highly controlled substance with strict rules. This affects anyone who makes, sells, studies, or even possesses 3-MeO-PCP, who will face serious legal consequences. This move helps the U.S. follow international drug laws and keeps communities safer.
Analyzed Economic Effects
5 provisions identified: 1 benefits, 4 costs, 0 mixed.
3‑MeO‑PCP Placed Into Schedule I
Starting April 22, 2026, the Drug Enforcement Administration places 3-methoxyphencyclidine (3-MeO-PCP) in Schedule I of the Controlled Substances Act. That means possession, manufacture, distribution, importation, exportation, or other handling of 3-MeO-PCP is subject to the strict criminal, civil, and administrative penalties that apply to Schedule I substances.
DEA Registration Required to Handle 3‑MeO‑PCP
If you handle 3-MeO-PCP (manufacture, distribute, research with, import, export, or possess), you must register with DEA under 21 U.S.C. 822, 823, 957, and 958 and follow 21 CFR parts 1301 and 1312. Any person who currently handles 3-MeO-PCP and is not registered must submit an application and may not continue to handle it unless DEA approves the registration before the effective date.
Strict Compliance Rules for Registrants
DEA registrants handling 3-MeO-PCP must follow Schedule I controls including security requirements, labeling and packaging rules, quotas for manufacture, and recordkeeping and reporting. Registrants must take an initial inventory on the date they first handle controlled substances and thereafter inventory all controlled substances (including 3-MeO-PCP) every two years, and must comply with disposal rules and order form, import/export, and quota requirements.
Research Allowed but Requires Schedule I Registration
The final rule states that placing 3-MeO-PCP in Schedule I does not preclude research, but researchers must comply with DEA's Schedule I registration processes and requirements to conduct research legally. Those who wish to study 3-MeO-PCP must follow the DEA registration process for Schedule I substances before engaging in research.
DEA Says Limited Small‑Entity Economic Impact
DEA certifies under the Regulatory Flexibility Act that this final rule will not have a significant economic impact on a substantial number of small entities. The agency notes there appear to be no legitimate marketed sources for 3-MeO-PCP in the U.S., though legitimate suppliers sell it for scientific research, and there is no evidence of significant diversion from legitimate suppliers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2026-05607, Air Plan Approval; Texas; Reasonably Available Control Technology in the Dallas-Fort Worth Ozone Nonattainment Area
The EPA is giving a thumbs-up to Texas’ updated air pollution rules for big factories in the Dallas-Fort Worth area to help cut smog-causing chemicals. These changes kick in on April 22, 2026, and aim to make the air cleaner without breaking the bank. If you’re a business owner or live in DFW, expect better air and smarter pollution controls soon!
Next: 2026-05634, Minor Child Definition for Form LM-30 Labor Organization Officer and Employee Report
The Department of Labor is changing the definition of a “minor child” on the Form LM-30 from under 21 years old to under 18 years old. This update affects labor union officers and employees who file these reports, making it easier to comply without losing important financial disclosure info. The new rule kicks in April 22, 2026, for reports covering fiscal years starting July 1, 2026, with no extra costs involved.